Cargando…

Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study

Background: Non-alcoholic steatohepatitis ((NASH) is the progressive form of (non-alcoholic fatty liver disease) (NAFLD), which can progress to liver cirrhosis and hepatocellular carcinoma. There is no available reliable non-invasive diagnostic tool to diagnose NASH, and still the liver biopsy is th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albadawy, Reda, Agwa, Sara H. A., Khairy, Eman, Saad, Maha, El Touchy, Naglaa, Othman, Mohamed, Matboli, Marwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472260/ https://www.ncbi.nlm.nih.gov/pubmed/34572434 http://dx.doi.org/10.3390/biomedicines9091248

Ejemplares similares

Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study
por: Albadawy, Reda, et al.
Publicado: (2021)

Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death
por: Albadawy, Reda, et al.
Publicado: (2022)

Sparcl1 and Atherosclerosis
por: Cheng, Xu, et al.
Publicado: (2023)

SPARCL1 Influences Bovine Skeletal Muscle-Derived Satellite Cell Migration and Differentiation through an ITGB1-Mediated Signaling Pathway
por: Wang, Yuxin, et al.
Publicado: (2020)

Cryo-EM structure of human mitochondrial HSPD1
por: Klebl, David P., et al.
Publicado: (2020)

Role of human HSPE1 for OPA1 processing independent of HSPD1
por: Yeung, Nelson, et al.
Publicado: (2023)

Prognostic value of SPARCL1 in patients with colorectal cancer
por: Han, Wei, et al.
Publicado: (2018)

Effects of SPARCL1 on the proliferation and differentiation of sheep preadipocytes
por: Xiao, Cheng, et al.
Publicado: (2021)

Associations of tumor suppressor SPARCL1 with cancer progression and prognosis
por: Li, Ting, et al.
Publicado: (2017)

Mutations in Hevin/Sparcl1 and risk of autism spectrum disorder
por: Taketomi, Takumi, et al.
Publicado: (2022)

HSPD1 Interacts with IRF3 to Facilitate Interferon-Beta Induction
por: Lin, Lan, et al.
Publicado: (2014)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis
por: He, Kangwei, et al.
Publicado: (2022)

Prospective insight into the role of benzyl propylene glycoside as a modulator of the cGAS-STING signaling pathway in the management of nonalcoholic fatty pancreas animal model
por: Albadawy, Reda, et al.
Publicado: (2023)

Defective myelination in mice harboring hypomyelinating leukodystrophy-associated HSPD1 mutation
por: Miyamoto, Yuki, et al.
Publicado: (2017)

miR-382 Contributes to Renal Tubulointerstitial Fibrosis by Downregulating HSPD1
por: Fang, Yi, et al.
Publicado: (2017)

A recurrent de novo HSPD1 variant is associated with hypomyelinating leukodystrophy
por: Cömert, Cagla, et al.
Publicado: (2020)

Disadvantages of a SPARCling defense
por: Bashyam, Hema
Publicado: (2008)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Data supporting mitochondrial morphological changes by SPG13-associated HSPD1 mutants
por: Miyamoto, Yuki, et al.
Publicado: (2016)

Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting
por: Parma, Beatrice, et al.
Publicado: (2021)

Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues
por: Klingler, Anika, et al.
Publicado: (2020)

SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer
por: Zhang, Hai-Ping, et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Independent occurrence of de novo HSPD1 and HIP1 variants in brothers with different neurological disorders – leukodystrophy and autism
por: Yamamoto, Toshiyuki, et al.
Publicado: (2018)

Self-reported causes of cancer among 6881 survivors with 6 tumour types: results from the PROFILES registry
por: Vlooswijk, Carla, et al.
Publicado: (2021)

Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma
por: Luo, Hao-Lun, et al.
Publicado: (2019)

Matricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease
por: Regensburger, Daniela, et al.
Publicado: (2021)

BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH
por: Baboota, Ritesh K., et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_08a5ujmf6kus9e9p45pk73hhbh